Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | FFAR2 | O15552 | 7/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | STK3 | Q13188 | 1/20 | 0.37 |
| ▸ | STK26 | Q9P289 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23344681 | 0.85 | FFAR2 (0.40) | LRRK2FFAR2 | |
| SCHEMBL23344656 | 0.84 | AR (0.42) | FFAR2 | |
| SCHEMBL30417107 | 0.79 | FFAR2 (0.45) | LRRK2CDC7FFAR2STK3STK26 | |
| SCHEMBL31718061 | 0.78 | CHI3L1 (0.49) | LRRK2CDC7FFAR2 | |
| SCHEMBL23344647 | 0.77 | CYP1A2 (0.45) | LRRK2PIK3CAPIK3CDPIK3CGMTOR | |
| SCHEMBL14436539 | 0.77 | CYP1A2 (0.45) | — | |
| SCHEMBL23344783 | 0.76 | CYP1A2 (0.48) | — | |
| SCHEMBL22717519 | 0.73 | KMT2A (0.62) | CDC7FFAR2 | |
| SCHEMBL29574339 | 0.73 | KMT2A (0.62) | CDC7FFAR2 | |
| SCHEMBL23344776 | 0.72 | MTOR (0.44) | PIK3CAPIK3CDMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INSTITUTE, INC | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | SCN8A, SCN5A, SCN2A | LRRK2 1681/4885CDC7 2537/4885FFAR2 4053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.